**Author’s response to reviews**

**Title:** All-trans retinoic acid stimulates the secretion of TGF-β2 via the phospholipase C but not the adenylyl cyclase signaling pathway in retinal pigment epithelium cells

**Authors:**

Daren Zhang (zhangdaren@csu.edu.cn)
Shuirong Liu (128167864@qq.com)
Shuyu Hu (hushuyu1995@163.com)
Hui Tao (975598455@qq.com)
Renhong Tang (trh_1@126.com)
Zhihong Deng (daneyldeng@126.com)
Jia Tan (jasmintj@126.com)

**Version:** 3  **Date:** 07 Dec 2018

**Author’s response to reviews:**

Author Reply to comments

BOPH-D-18-00528R2

All-trans retinoic acid stimulates the secretion of TGF-β2 via the phospholipase C but not the adenylyl cyclase signaling pathway in retinal pigment epithelium cells.

Daren Zhang; Zhihong Deng; Jia Tan; Shuirong Liu; Shuyu Hu; Hui Tao; Renhong Tang

BMC Ophthalmology

Dear Dr Deng,

Thank you for amending your manuscript according to our requests. However, there are a few minor revisions that are necessary before we can accept the manuscript for publication:
1. Unfortunately, the current submission still contains some textual overlap with other previously published works, in particular:


This overlap mainly exists in the Methods sections.

While we understand that this is work that you have previously published, and some of the same ideas are contained in these publications, please be aware that we cannot condone the use of text from previously published work.

If there is overlap in the Methods section, please ensure to summarize the methods and cite the source.

Please re-phrase these sections to minimise overlap.

Reply: we re-phrased the Methods section by summarizing the methods.

2. In the section 'Funding', please also describe the role of the funding body/bodies in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Reply: we revised the funding section as follows :“The study is supported by Hunan Science and Technology Planning Project (2015DK3007) which affords funding only, but has not any other contribution to our research.”

3. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Reply: we uploaded revised manuscript as described.
Please also take a moment to check our website at https://boph.editorialmanager.com/ for any additional comments that were saved as attachments.

Once you have made the necessary corrections, please submit a revised manuscript online at:

https://boph.editorialmanager.com/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://boph.editorialmanager.com/. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 12 Dec 2018.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies. To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - http://www.biomedcentral.com/about/editorialpolicies#authorship. Please note that incomplete forms will be rejected. Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.
We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Amy Branch-Hollis
BMC Ophthalmology
https://bmcophthalmol.biomedcentral.com/

Method:

> As cell lines obtained commercially, please also state catalogue/identification number.

Reply: In this study, human RPE cell line (D407) was obtained from the Retinal Cell Biology Laboratory, University of South Carolina (Columbia, South Carolina, USA) for scientific research. It is not obtained commercially, and we have been published another paper about the D407.


Funding:

> We note that you have not included a ‘Funding’ section in the Declarations. All sources of funding for the research reported should be declared. If no funding was obtained for your study we still require this section to be included with the statement “No funding was obtained for this study”.

Reply: we revised it.
Acknowledgements:

> We note that you have not included an acknowledgements section in the Declarations. If you have no acknowledgements please put ‘Not Applicable’ in this section.

Reply: we revised it.

Figure legends:

> Please remove the figure legends embedded within the figure files. All figure titles/legends should be listed under a separate heading of 'Figure Legends' after the References.

BMC Ophthalmology operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers.

Reply: we revised it.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Ophthalmology must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcophthalmol.biomedcentral.com/).
Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:

http://www.biomedcentral.com/about/editorialpolicies#Ethics

Availability of data and materials section:

http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials
Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy or email dataprotection@springernature.com. If you no longer wish to receive messages from this journal or you have questions regarding the Editorial Manager database and the publishing process, please email our publication office, stating the journal name(s) and your email address(es):

PublicationOfficeSPI@springernature.com

In compliance with data protection regulations, please contact the publication office if you would like to have your personal information removed from the database.